Skip to main content
Premium Trial:

Request an Annual Quote

Expression Pathology, Flagship Partner to Offer Translational Biomarker Services

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Expression Pathology and Flagship Biosciences today announced a service partnership to enable tissue translational biomarker development, validation, and application to support new drug development.

The new offering combines Expression's expertise in multiplex tissue proteomic assays using frozen formalin, paraffin-fixed tissues with Flagship's pathology expertise.

Based in Flagstaff, Ariz., Flagship provides digital pathology services. Expression is based in Gaithersburg, Md., and develops assays to measure functional tissue proteins.

Customers of both firms will now be able to "leverage expertise with tissue biomarkers to quickly develop quantitative evidence-based assays using the combined know how of mass spec tissue analysis and digital pathology," Flagship said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.